Salvage chemotherapy with docetaxel and epirubicin for advanced/metastatic gastric cancer

Jae Yun Lim, Jae Yong Cho, Yong Han Paik, Dong Ki Lee, Sang In Lee, Hyo Jin Park, Se Joon Lee, Kwan Sik Lee, Dong Sup Yoon, Seung Ho Choi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: We conducted a phase II study to assess the efficacy and tolerability of docetaxel and epirubicin as salvage chemotherapy in advanced/metastatic gastric cancer patients with documented progression after 5-fluorouracil/platinum-based combination chemotherapy. Methods: Docetaxel 75 mg/m2 and epirubicin 50 mg/m2 were administered on days 1 and 2, respectively, every 3 weeks. Treatment continued until progression of disease or until a life-threatening adverse event occurred. The primary objectives of this study were to evaluate the safety profile and response rate to this treatment regimen. Results: Thirty-four patients were enrolled in the study. Twenty-six patients had locally advanced or metastatic disease at the time of diagnosis, and 8 patients had recurrent disease after surgical resection of the primary tumor. A total of 157 chemotherapy cycles were administered. Seven (21.8%) patients had a partial response and 12 (37.5%) patients had stable disease. The median time to progression and overall survival were 4.1 and 13.4 months, respectively. Grade III/IV hematologic toxicities included neutropenia in 16 patients (47%) and febrile neutropenia in 8 patients (24%). Nonhematologic toxicities were rare. Conclusion: A combination of chemotherapy with docetaxel and epirubicin showed moderate activity as salvage treatment in advanced/metastatic gastric cancer, especially in patients who had responded to prior chemotherapy.

Original languageEnglish
Pages (from-to)2-8
Number of pages7
JournalOncology
Volume73
Issue number1-2
DOIs
Publication statusPublished - 2008 Mar 1

Fingerprint

docetaxel
Epirubicin
Stomach Neoplasms
Drug Therapy
Combination Drug Therapy
Salvage Therapy
Febrile Neutropenia
Neutropenia
Platinum

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Lim, Jae Yun ; Cho, Jae Yong ; Paik, Yong Han ; Lee, Dong Ki ; Lee, Sang In ; Park, Hyo Jin ; Lee, Se Joon ; Lee, Kwan Sik ; Yoon, Dong Sup ; Choi, Seung Ho. / Salvage chemotherapy with docetaxel and epirubicin for advanced/metastatic gastric cancer. In: Oncology. 2008 ; Vol. 73, No. 1-2. pp. 2-8.
@article{18878a2eda4042b2a2f422f8a9677436,
title = "Salvage chemotherapy with docetaxel and epirubicin for advanced/metastatic gastric cancer",
abstract = "Background: We conducted a phase II study to assess the efficacy and tolerability of docetaxel and epirubicin as salvage chemotherapy in advanced/metastatic gastric cancer patients with documented progression after 5-fluorouracil/platinum-based combination chemotherapy. Methods: Docetaxel 75 mg/m2 and epirubicin 50 mg/m2 were administered on days 1 and 2, respectively, every 3 weeks. Treatment continued until progression of disease or until a life-threatening adverse event occurred. The primary objectives of this study were to evaluate the safety profile and response rate to this treatment regimen. Results: Thirty-four patients were enrolled in the study. Twenty-six patients had locally advanced or metastatic disease at the time of diagnosis, and 8 patients had recurrent disease after surgical resection of the primary tumor. A total of 157 chemotherapy cycles were administered. Seven (21.8{\%}) patients had a partial response and 12 (37.5{\%}) patients had stable disease. The median time to progression and overall survival were 4.1 and 13.4 months, respectively. Grade III/IV hematologic toxicities included neutropenia in 16 patients (47{\%}) and febrile neutropenia in 8 patients (24{\%}). Nonhematologic toxicities were rare. Conclusion: A combination of chemotherapy with docetaxel and epirubicin showed moderate activity as salvage treatment in advanced/metastatic gastric cancer, especially in patients who had responded to prior chemotherapy.",
author = "Lim, {Jae Yun} and Cho, {Jae Yong} and Paik, {Yong Han} and Lee, {Dong Ki} and Lee, {Sang In} and Park, {Hyo Jin} and Lee, {Se Joon} and Lee, {Kwan Sik} and Yoon, {Dong Sup} and Choi, {Seung Ho}",
year = "2008",
month = "3",
day = "1",
doi = "10.1159/000120027",
language = "English",
volume = "73",
pages = "2--8",
journal = "Oncology",
issn = "0030-2414",
publisher = "S. Karger AG",
number = "1-2",

}

Lim, JY, Cho, JY, Paik, YH, Lee, DK, Lee, SI, Park, HJ, Lee, SJ, Lee, KS, Yoon, DS & Choi, SH 2008, 'Salvage chemotherapy with docetaxel and epirubicin for advanced/metastatic gastric cancer', Oncology, vol. 73, no. 1-2, pp. 2-8. https://doi.org/10.1159/000120027

Salvage chemotherapy with docetaxel and epirubicin for advanced/metastatic gastric cancer. / Lim, Jae Yun; Cho, Jae Yong; Paik, Yong Han; Lee, Dong Ki; Lee, Sang In; Park, Hyo Jin; Lee, Se Joon; Lee, Kwan Sik; Yoon, Dong Sup; Choi, Seung Ho.

In: Oncology, Vol. 73, No. 1-2, 01.03.2008, p. 2-8.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Salvage chemotherapy with docetaxel and epirubicin for advanced/metastatic gastric cancer

AU - Lim, Jae Yun

AU - Cho, Jae Yong

AU - Paik, Yong Han

AU - Lee, Dong Ki

AU - Lee, Sang In

AU - Park, Hyo Jin

AU - Lee, Se Joon

AU - Lee, Kwan Sik

AU - Yoon, Dong Sup

AU - Choi, Seung Ho

PY - 2008/3/1

Y1 - 2008/3/1

N2 - Background: We conducted a phase II study to assess the efficacy and tolerability of docetaxel and epirubicin as salvage chemotherapy in advanced/metastatic gastric cancer patients with documented progression after 5-fluorouracil/platinum-based combination chemotherapy. Methods: Docetaxel 75 mg/m2 and epirubicin 50 mg/m2 were administered on days 1 and 2, respectively, every 3 weeks. Treatment continued until progression of disease or until a life-threatening adverse event occurred. The primary objectives of this study were to evaluate the safety profile and response rate to this treatment regimen. Results: Thirty-four patients were enrolled in the study. Twenty-six patients had locally advanced or metastatic disease at the time of diagnosis, and 8 patients had recurrent disease after surgical resection of the primary tumor. A total of 157 chemotherapy cycles were administered. Seven (21.8%) patients had a partial response and 12 (37.5%) patients had stable disease. The median time to progression and overall survival were 4.1 and 13.4 months, respectively. Grade III/IV hematologic toxicities included neutropenia in 16 patients (47%) and febrile neutropenia in 8 patients (24%). Nonhematologic toxicities were rare. Conclusion: A combination of chemotherapy with docetaxel and epirubicin showed moderate activity as salvage treatment in advanced/metastatic gastric cancer, especially in patients who had responded to prior chemotherapy.

AB - Background: We conducted a phase II study to assess the efficacy and tolerability of docetaxel and epirubicin as salvage chemotherapy in advanced/metastatic gastric cancer patients with documented progression after 5-fluorouracil/platinum-based combination chemotherapy. Methods: Docetaxel 75 mg/m2 and epirubicin 50 mg/m2 were administered on days 1 and 2, respectively, every 3 weeks. Treatment continued until progression of disease or until a life-threatening adverse event occurred. The primary objectives of this study were to evaluate the safety profile and response rate to this treatment regimen. Results: Thirty-four patients were enrolled in the study. Twenty-six patients had locally advanced or metastatic disease at the time of diagnosis, and 8 patients had recurrent disease after surgical resection of the primary tumor. A total of 157 chemotherapy cycles were administered. Seven (21.8%) patients had a partial response and 12 (37.5%) patients had stable disease. The median time to progression and overall survival were 4.1 and 13.4 months, respectively. Grade III/IV hematologic toxicities included neutropenia in 16 patients (47%) and febrile neutropenia in 8 patients (24%). Nonhematologic toxicities were rare. Conclusion: A combination of chemotherapy with docetaxel and epirubicin showed moderate activity as salvage treatment in advanced/metastatic gastric cancer, especially in patients who had responded to prior chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=41549147442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41549147442&partnerID=8YFLogxK

U2 - 10.1159/000120027

DO - 10.1159/000120027

M3 - Article

C2 - 18332648

AN - SCOPUS:41549147442

VL - 73

SP - 2

EP - 8

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 1-2

ER -